The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

One in three women diagnosed with MS will subsequently conceive, therefore consideration of the maternal-infant dyad is ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing ...

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

The presentation highlighted that ocrelizumab may be safe during pregnancy, and treatment with the drug may be resumed while breastfeeding. In the session, Genentech stated that one in three women ...

In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with relapsing multiple ...

Neurologist Stephen Hauser, MD, of the University of California San Francisco, and epidemiology professor Alberto Ascherio, ...

The clinical experts explained that ocrelizumab and ofatumumab are considered high-efficacy DMTs, and that these were the most relevant comparators for cladribine. While ponesimod is also considered ...